近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Guan, T.; Li, M.; Song, Y.; Chen, J.; Tang, J.; Zhang, C.; Wen, Y.; Yang, X.; Huang, L.; Zhu, Y.; Wang, H.; Ding, K.* Zheng, J.* Zhang, H.*; Liu, T.* Phosphorylation of USP29 by CDK1 Governs TWIST1 Stability and Oncogenic Functions. Adv. Sci. 2023 https://doi.org/10.1002/advs.202205873
Lv, S.; Xu, F.; Fan, Y.; Ding, K.* & Li, Z.* Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer. J. Med. Chem. 2023, https://doi.org/10.1021/acs.jmedchem.2c01889
He, R.; Song, Z.; Bai, Y.; He, S.; Huang, J.; Wang, Y.; Zhou, F.; Huang, W.; Guo, J.; Wan, Z.; Tu, Z.-C.; Re, X.; Zhang, Z.; Xu, J.; & Ding, K.* Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells. J. Med. Chem. 2023, 66(3), 1873–1891.
Lai, M.; Zhang, T.; Chen, H.; Song, P.; Tong, L.; Chen, J.; Liu, Y.; Ning, Y.; Feng, F.; Li, Y.; Tang, H.; Chen, Y.; Fang, Y.; Lu, X.; Geng, M.; Ding, K.; * Yu, K.*; Ding, J.*; Xie, H.* Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo. J. Cancer, 2023, 14(1), 152.
Zhang, Y.; Chan, S.; He, R.; Liu, Y.; Song, X.; Tu, Z.-Z.; Ren, X.; Zhou, Y.; Zhang, Z.*; Wang, Z.*; Zhou, F.*; Ding. K.* 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl) amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. Eur. J. Med. Chem. 2022, 244, 114862
Wang, Y.; Zhou, Y.; Shi, C.; Liu, J.; Lv, G.; Huang, H, Li, S.; Duan, L.; Zheng, X.; Liu, Y.; Zhou, H.; Wang, Y.; Ding, K.*; Sun, P.*; Huang, Y.*; Lu, X.*; Zhang, Z.-M.* A toxin-deformation dependent inhibition mechanism in the T7SS toxin-antitoxin system of Gram-positive bacteria. Nature Commu. 2022, 13, 6434.
Wang, J.; Zhou, Y.; Tang, X.; Yu, X.; Wang, Y.; Chan, S.; Song, X.; Tu, Z.-C.; Zhang, Z.-M.; Lu, X.*; Zhang, Z.*; Ding, K.* JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo. Molecules 2022, 27, 6500.
Shu, S.; Liu, H.; Yang, J.; Tang, H.; Li, H.; Liu, Z.; Zhou, M.; Zhu, F.; Hu, Z.; Ding, K.; Lu, X.; Nie, J.* Targeted inhibition of ZAK ameliorates renal interstitial fibrosis. 2022, 246, 49 – 65. DOI: 10.1016/j.trsl.2022.03.002
Chen, Z.; Ke, R.; Song, Z.; Zhou, Y.; Ren, X.; Huang, W.; Wang, Z.*, Ding, K.* A novel photocaged B-RafV600E inhibitor toward precise melanoma treatment. Bioorg. Med. Chem. Lett. 2022, 64, 128683
Shen, C.; Zhang, D.; Xu, F.; Yang, Y.; Tan, Y.; Zhang, Q.*; Li, L.; Ding, K.; Li, Z.* Two-photon fluorescent turn-on probes for highly efficient detection and profiling of thiols in live cells and tissues. Biol. Chem. 2022 403, 445 – 451.
Lyu, P.; Jiang, K.; Zhou, Y.; Hu, J.; Chang, Y.; Zhang, Z.; Hunag, M, Zhang, Z.-M.; Ding, K.*; Hao, P.; *, Lin, L.*; Li, Z.* Proteome-wide Identification of Off-Targets of a Potent EGFRL858R/T790MMutant Inhibitor. ACS Med. Chem. Lett. 2022, 13, 292-297.
Liu, Y.; Lai, M.; Li, S.; Wang, Y.; Feng, F.; Zhang, T.; Tong, L.; Zhang, M.; Cheng, H.; Chen, Y.; Song, P.; Li, Y.; Bai, G.；Ning, Y.； Tang，H.; Fang, Y.; Chen, Y.; Lu, X.; Geng, M.; Ding, K*; Yu, K.*; Xie, H.*; Ding, J.* LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Science, 2022, 113, 709-720.
Si. H.; Wang, J.; He, R.; Yu, X.; Li, S.; Huang, J.; Li, J.; Tang, X.; Song, X.; Tu, Z.-C.; Zhang, Z.*, Ding, K.* Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor. Frontiers in Oncology 2022, 11, 807200.
Chan, S.; Zhang, Y.; Wang, J.; Yu, Q.; Peng, X.; Zou, J.; Zhou, L.; Tan, L.; Duan, Y.; Zhou, Y.; Hur, H.; Ai, J.*; Wang, Z.*; Ren, X.*; Zhang, Z.*; Ding, K*. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. J. Med. Chem. 2022, 65, 22, 15374–15390.
Xu, F.; Zhang, X.; Chen, Z.; He, S.; Guo, J.; Yu, L.; Wang, Y.; Hou, C.; AI-furas, H.; Zheng, Z.; Smaill, J. B.; Patterson, A. V.; Zhang, Z.-M.; Chen, L.*; Ren, X.*; and Ding, K.* Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells. J. Med. Chem. 2022, 65, 20, 14032–14048.
Yang, J.; Chang, Y.; Tien, J. C.-Y.; Wang, Z.; Zhou, Y.; Zhang, P.; Huang, W.; Vo, J.; Apel, I. J.; Wang, C.; Zeng, V. Z.; Cheng, Y.; Li, S.; Wang, G. X.*; Chinnaiyan, A. M.*; and Ding, K.* Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13. J. Med. Chem. 2022, 65, 16, 11066–11083
Li, S.; Zhang, P.; Xu, F.; Hu, S.; Liu, J.; Tan, Y.; Tu, Z.; Sun, H.; Zhang, Z.-M.; He, Q.-Y.; Sun, P.*; Ding, K.*; and Li, Z.* Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors. J. Med. Chem. 2022, 65, 15, 10408–10418.
Li, S.; Si, H.; Song, X.; Lei, C.; He, X.; Wang, J.; Liu, Y.; Zhou, Y.; Song,J.-G.; Peng, L.; Tang, X.; Chan, S.; Ren, X.; Tu, Z.-C.; Li*, Z.*; Wang*, Z.&； Zhang, Z.*; and Ding, K.* Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant. J. Med. Chem. 2022, 65, 15, 10674–10690.
Chen, H.; Lai, M.; Zhang, T.; Chen, Y.; Tong, L.; Zhu, S.; Zhou, Y.; Ren, X.; Ding, J.; Xie, H.*; Lu, X.*; and Ding, K.* Conformational Constrained 4-(1-Sulfonyl-3-indol)yl -2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J. Med. Chem. 2022, 65, 9, 6840–6858.
Wang, Z.; Wang, J.; Wang, Y.; Xiang, S.; Song, X.; Tu, Z.-C.; Zhou, Y.; Zhang, Z.-M.*; Zhang, Z.*, Ding, K.*; and Lu, X.* Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance. J. Med. Chem. 2022, 65, 8, 6325–6337.
Zhang, Z.; Li, J.; Chen, H.; Huang, J.; Song, X.; Tu, Z.-C.; Zhang, Z.; Peng, L.*; Zhou, Y.*; and Ding, K.* Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors. J. Med. Chem. 2022, 65, 4, 3249–3265.
Mao, L.; Peng, L.; Ren, X.; Chu, Y.; Lin, W.; Nie, T.; Lin, W.; Libby, A.; Xu, Y.; Chang, Y.; Lei, C.; Lommes, K.; Liu, J.; Levi, M.; Wu, D.; Hui, X*; and Ding, K.* Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance. ACS Bio. Med. Chem. Au 2022, 2, 3, 282–296.
Lu, J.; Huang, Y.; Huang, J.; He, R.; Huang, M.; Lu, X.; Xu, Y.; Zhou, F.*; Zhang, Z.* and Ding, K.* Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders. J. Med. Chem. 2022, 65, 3, 2313–2328.
Wang, Z.*; Huang, W.; Zhou, K.; Ren, X.; and Ding, K.* Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery? J. Med. Chem. 2022, 65, 3, 1735–1748.
Li, S.; Zhang, T.; Zhu, S.-J.; Lei, C.; Lai, M.; Peng, L.; Tong, L.; Pang, Z.; Lu, X.; ding, J.; Ren, X.*; Yun, C.-H.*; Xie, H.*; and Ding, K.* Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants. ACS Med. Chem. Lett. 2022, 13, 2, 196–202.
Zhang, Z.; Wang, YJ.; Chen, XJ.; Song, XJ.; Tu, ZC.; Chen, YH.; Zhang, ZM.; Ding, K.* Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design. Bioorgan. Med. Chem. 2021, 50, 116457, https://doi.org/10.1016/j.bmc.2021.116457
Jin, YL.; Ding, K.; Li, HL.; Xue, MZ.; Shi, XK.; Wang, CY .; Pan, JX. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFR alpha: roles of Mcl-1 and beta-catenin. Mol. Cancer. 2021, 20(1): 137, https://dx.doi.org/10.1186%2F1476-4598-13-17
Xia, Y.; Zou, R.; Escouboue, M.; Zhong, L.; Zhu, CJ.; Pouzet, C.; Wu, XQ.; Wang, YJ .; Lv, G.; Zhou, HB.; Sun, PH.*; Ding, K.*; Deslandes, L.*; Yuan, SG.*; Zhang, ZM.* Secondary-structure switch regulates the substrate binding of a YopJ family acetyltransferase. Nat. Commun. 2021, 12, 5969, https://dx.doi.org/10.1038%2Fs41467-021-26183-1
Fan, YL.; Si, HF.; Zhang, Z.; Zhong, L.; Sun, HY.; Zhu, CJ.; Yin, ZB.; Li, HL.; Tang, GH.; Yao, SQ.; Sun, PH.*; Zhang, ZM.*; Ding, K.*; Li, ZQ.* J. Med. Chem. 2021, 64, 21, 15582-15592, https://doi.org/10.1021/acs.jmedchem.0c02024
Shen, CZ.; Zhang, DT.; Xu, F.; Yang, Y.; Tan, Y.; Zhao, Q.; Li, L.; Ding, K.*; Li, ZQ.* Two-photon fluorescent turn-on probes for highly efficient detection and profiling of thiols in live cells and tissues. Biol. Chem. 2021, 10.1515/hsz-2021-0189
Liu, Y.; Lv, S.; Peng, L.; Xie, C.; Gao, L.; Sun, H.; Lin, L.; Ding, K.*; Li, Z.* Development and application of novel electrophilic warheads in target identification and drug discovery. Biochemical Pharmacology 2021, 190, 114636, https://doi.org/10.1016/j.bcp.2021.114636
Jiang, K., Tang, X., Guo, J., He, R., Chan, S., Song, X., Tu, Z., Wang, Y., Ren, X., Ding, K.*, Zhang, Z.* GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. Cancer medicine. 2021, 10(14), 4874–4884. https://doi.org/10.1002/cam4.4041
Dai W., Liu S., Wang S., Zhao L., Yang X., Zhou J., Wang Y., Zhang J., Zhang P., Ding K., Li Y., Pan J.*. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma. Signal Transduct Target Ther. 2021, 6(1), 176, https://dx.doi.org/10.1038%2Fs41392-021-00563-x
Jiang, L., Wang, Y., Li, Q., Tu, Z., Zhu, S., Tu, S., Zhang, Z.*, Ding, K*, Lu, X.* Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta pharmaceutica Sinica. B. 2021, 11(5), 1315–1328, https://doi.org/10.1016/j.apsb.2020.11.009
ng, W.; Chen, X.; Jiang, K.; Song, X.; Huang, M.; Tu, Z.-C.; Zhang, Z.; Lin, X.; Ortega, R.; Patterson, A. V.; Smaill, J. B.; Ding, K.; Chen, S.*, Chen, Y.*, Lu, X.* Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. ACS Med. Chem. Lett. 2021, 12, 647–652, https://doi.org/10.1021/acsmedchemlett.1c00052
ang, M.; Huang, Y.; Guo, J.; Yu, L.; Chang, Y.; Wang, X.; Luo, J.; Huang, Y.; Tu, Z.; Lu, X.; Xu, Y.; Zhang, ZM.*; Zhang, Z.*; Ding, K.* Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. Eur. J. Med. Chem. 2021, 211, 113023. https://doi.org/10.1016/j.ejmech.2020.113023
ao, Y.; Tien, J. E. C.; Simko, S. A.; Rajendiran, T.; Vo, J. N; Delekta, A. D.; Wang, L.; Xiao, L.; Hodge, N. B.; Desai, P.; Mendoza, S.; Juckette, K.; Xu, A.; Soni, T.; Su, F.; Wang, R.; Cao, X.; Yu, J.; Kryczek, I.; Wang, X.-M.; Wang, X.; Siddiqui, J.; Wang, Z.; Bernard, A.; Fernandez-Salas, E.; Navone, N. M.; Ellison, S. J.; Ding, K.; Eskelinen, E.-L.; Klionsky, D. J.; Zou, W.; Chinnaiyan, A. M. Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer 2021, 2, 978–993
Fan, Z.; Tian, Y.; Chen, Z.; Liu, L.; Zhou, Q.; He, J.; Coleman, J.; Dong, C.; Li, N.; Huang, J.; Xu, C.; Zhang, Z.; Gao, S.; Zhou, P.*; Ding, K.*; & Chen, L.* Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors. EMBO Mol. Med. 2020, e11571, https://doi.org/10.15252/emmm.201911571
Zhang, X.; Xu, F.; Tong, L.; Zhang, T.; Xie, H.; Lu, X.; Ren, X.*; Ding, K.* Design and synthesis of selective degraders of EGFRL858R/T790M mutant. Eur. J. Med. Chem. 2020, https://doi.org/10.1016/j.ejmech.2020.112199.
Zhang, T.; Qu, R.; Chan, S.; Lai, M; Tong, L.; Feng, F.; Chen, H.; Song, T.; Song, P.; Bai, G.; Liu, Y.; Wang, Y.; Li, Y.; Su, Y.; Shen, Y.; Sun, Y.; Chen, Y.; Geng, M.; Ding, K.*; Ding, J.* and Xie, H.* Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol. Cancer 2020, https://doi.org/10.1186/s12943-020-01202-9.
Ma, N.; Hu, J.; Zhang, Z.-M.; Liu, W.; Huang, M.; Fan, Y.; Yin, X.; Wang, J.*; Ding, K.*; Ye, W* and Li. Z.* 2H-Azirine-Based Reagents for Chemoselective Bioconjugation at Carboxyl Residues Inside Live Cells. J. Am. Chem. Soc. 2020, https://doi.org/10.1021/jacs.9b12116
Guo, J.; Zhang, Z.; Ding, K.* A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present). Expert Opinion on Therapeutic Patents 2020, https://doi.org/10.1080/13543776.2020.1732925
Jiang, L.; Wang, X.; Wang, Y.; Xu, F.; Zhang, Z.*; Ding, K.*; Lu, X.* The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents. RSC Med. Chem. 2020, 11, 293-296
Xu, J.; Zhang, Z.; Lin, L.; Sun, H.; White, L. V.; Ding, K.*; Li, Z.*Quantitative Proteomics Reveals Cellular Off-Targets of a DDR1 Inhibitor. ACS Med. Chem. Lett. 2020, https://doi.org/10.1021/acsmedchemlett.9b00658
Mo, C.; Zhang, Z.; Li, Y.; Huang, M.; Zou, J.; Luo, J.; Tu, Z.-C.; Xu, Y.; Ren, X.*; Ding, K.* and Lu, X. * Design and Optimization of 3'-(Imidazo[1,2-a]pyrazin-3-yl)-[1,1'-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors. ACS Med. Chem. Lett. 2020, 11(3), 379-384.
Xu, J.; Li, X.; Ding, K.*; Li, Z.* Applications of Activity-Based Protein Profiling (ABPP) and Bioimaging in Drug Discovery. Chemistry - An Asian J. 2020, 15(1), 34-41.
Lu, X.*; Smail, J. B. Ding, K.* New Promise and Opportunities for Allosteric Kinase Inhibitors. New Promise and Opportunities for Allosteric Kinase Inhibitors. Angew. Chem. Int. Ed. 2020 https://doi.org/10.1002/anie.201914525
Chang, Y.; Xu, S.; Ding, K.* Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. J. Med. Chem. 2019, 62, 8951-8952.
Hu. X.; Xun, Q.; Zhang, T.; Li, Q.; Tang, L.; Lai, M.; Huang, T.; Yun, C.-H.*; Xie, H.*; Ding, K.*; and Lu, X.* 2-Oxo-3, 4-dihydropyrimido [4, 5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant. Chin. Chem. Lett. 2019, https://doi.org/10.1016/j.cclet.2019.09.044.
Zhu, D.; Huang, H.; Pinkas, D. M.; Luo, J.; Ganguly,D; Fox, A. E.; Arner, E.; Xiang, Q.; Tu, Z.; Bukkock, A. N.* Brekken, R. A.* Ding, K.* Lu, X.* 2-Amino-2, 3-dihydro-1 H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. J. Med. Chem. 2019, 62, 7431-7444.
Shen. J.; Zhang, T.; Zhu, S.-J.; Sun, M.; Tong, L.; Lai, M.; Zhang, R.; Xu, W.; Wu, R.; Ding, J.; Yun, C.-H.* Xie, H.* Lu, X.* Ding, K.* Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S). J. Med. Chem. 2019, 62, 7302-7308.
Lin, X.; Yosaatmadja,Y.; Kalyukina, M.; Middleditch, M. J.; Zhang, Z.; Lu, X.; Ding, K.; Patterson, A. V.; Smaill, J. B.; Squire C. J. Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. ACS Med. Chem. Lett. 2019, 10 (8), 1180-1186.
Chang, Y.; Zhu, D.; Guo, H.; Yin, X.; Ding, K.; Li, Z.* Crenolanib‐Derived Probes Suitable for Cell‐and Tissue‐Based Protein Profiling and Single‐Cell Imaging. ChemBioChem 2019, 20 (14), 1783-1788.
Cui, S.; Wang, Y.; Wang, Y.; Tang, X.; Ren, X.; Zhang, L.; Xu, Y.; Zhang, Z.*; Zhang, Z.*; Lu, X.*; Ding, K.* Design, synthesis and biological evaluation of 3-(imidazo [1, 2-a] pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitor. Eur. J. Med. Chem. , 2019, 179, 470-482.
Xun, Z.; Wang, Z.; Hu, X.; Ding, K.*; Lu, X.* Small-Molecule CSF1R Inhibitors as Anticancer Agents. Curr. Med. Chem. 2019 doi: 10.2174/1573394715666190618121649.
Yang, Z.; Shibu, M. A.; Kong. L.; BadrealamKhan, F.; Luo, J.; Huang, Y.; Tu, Z.; Yun, C.*; Huang, C.-Y.*; Ding, K.*; Lu, X.* Design, Synthesis, and Structure–Activity Relationships of 1, 2, 3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitor. J. Med. Chem. 2019, https://doi.org/10.1021/acs.jmedchem.9b00664.
Zou, J.; Zhang, Z.*; Xu, F.; Cui, S.; Qi, C.; Luo, J.; Wang, Z.; Lu, X., Tu, Z.; Re, X.; Song, Y.*, Ding, K.* GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models. J. Drug Targeting 2019, 27 (4), 442-450.
Peng, L.*; Zhang, Z.; Lei, C.; Li, S.; Zhang, Z.; Ren, X.; Chang, Y.; Zhang, Y.; Xu, Y.; Ding, K.* Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation. ACS Med. Chem. Lett. 2019, 10, 767-772.
Tang, L.; Zhang, Z.; Gao, D.; Chan, S.; Luo, J.; T. Z.; Zhang, Z.; Ding, K.*; Ren, X.*; Lu, X.* Eur. J. Med. Chem. 2019, 166, 318-327.
Zhang, Y.; Wang, Y.; Guo, Y.; Liao, J.; Tu, Z.; Lu, Y.; Ding, K.; Tortorella, M. D., He, J. Identification and synthesis of low-molecular weight cholecystokinin B receptor (CCKBR) agonists as mediators of long-term synaptic potentiation. Med. Chem. Res. 2019, 28, 387-393.
Hu, X.; Wan, B.; Liu, Y.; Shen, J.; Franzblau, S. G.; Zhang, T.*; Ding, K.*; Lu, X. * Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents. ACS Med. Chem. Lett. 2019, 10, 295-299.
Ti, H.; Zhang, Y.; Liang, X.; Li, R.; Ding, K.*; Zhang, X.* Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). J. Med. Chem. 2019, 62, 5944-5978.
Liu, W.; Zhang, Z.; Zhang, Z.; Hao, P; Ding, K.; Li, Z. Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer. Chem. Comm. 2019, 55 (11), 1596-1599.
Wang, X.; Ma, N.; Wu, R.; Ding, K., Li, Z. A novel reactive turn-on probe capable of selective profiling and no-wash imaging of Bruton's tyrosine kinase in live cells. Chem. Comm. 2019, 55 (24), 3473-3476.
Guo, C.; Chang, Y.; Wang, X.; Zhang, C.; Hao, P.; Ding, K.; Li, Z. Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening. Chem. Comm. 2019, 55 (6), 834-837.
京公网安备 11010802027423号